Company: BNBX
Filing Date: 2025-01-17
Form Type: 424B3
Source: 0001104659-25-004510
Chunk: 11

Company: BNB PLUS CORP.
Filing Date: 2025-01-17
Form: 424B3
Chunk 11
---
 new and existing LineaDNA IVT template customers to LineaIVT platform
customers to increase the Company’s mRNA-related TAM.

Until our GMP Site 1 to produce DNA critical
starting materials (DNA IVT templates) for mRNA manufacturing is operational we will not be able to realize significant revenues from
this business. If we were to expand our facilities to enable GMP production of LineaDNA for use as, or incorporation, into a biologic,
drug substance and/or drug product as planned for GMP Site 2, the additional CAPEX may be up to approximately $10 million which would
require additional funding. We anticipate upgrades to GMP Site 1 to enable the manufacture of LineaDNA for use as, or incorporation into,
a biologic, drug substance and/or drug product manufacture to cost less than $1 million. Potential upgrades to GMP Site 1 would not alter
its current footprint within our existing laboratory space. We anticipate that a GMP Site 2 would require us to acquire additional space.

<div align='center'>4</div>

MDx Testing Services

Through Applied DNA Clinical Labs, LLC (“ADCL”),
we leverage our expertise in DNA and RNA detection via PCR to provide and develop clinical molecular diagnostics and genetic (collectively
“MDx”) Testing Services. ADCL is a New York State Department of Health (“NYSDOH”) clinical laboratory improvement
amendments (“CLIA”)-certified laboratory which is currently permitted for virology and genetics (molecular). In providing
MDx Testing Services, ADCL employs its own or third-party molecular diagnostic tests.

We have successfully internally validated our
pharmacogenomics testing services (the “PGx Testing Services”). Our PGx Testing Services utilizes a 120-target PGx panel
test to evaluate the unique genotype of a specific patient to help guide the patient’s healthcare provider in making individual
drug therapy decisions. Our PGx Testing Services are designed to interrogate DNA targets on over 33 genes and provide genotyping information
relevant to certain cardiac, mental health, oncology, and pain management drug therapies.

On June 12, 2024 we received full approval
from NYSDOH for our PGx Testing Services. Recently published studies show that population-scale PGx enabled medication management can
significantly reduce overall population healthcare costs, reduce adverse drug events, and increase overall population wellbeing. These
benefits can result in significant cost savings to large entities and self-insured employers, the latter accounting